Ascendis Pharma(ASND) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was EUR 248 million, with full-year 2025 revenue totaling EUR 720 million, reflecting strong growth [20][21] - Europat revenue for Q4 was EUR 187 million, up from EUR 140 million in Q3, with full-year revenue reaching EUR 477 million [20][21] - SKYTROFA generated EUR 53 million in Q4, contributing to a total of EUR 206 million for the full year [20][21] - Operating profit for Q4 2025 was EUR 10 million, with operating cash flow of EUR 73 million [21] Business Line Data and Key Metrics Changes - Europat's U.S. patient prescriptions exceeded 5,300 from nearly 2,400 healthcare providers, indicating strong demand [8] - SKYTROFA holds a market share of approximately 7% in the U.S. for growth hormone deficiency treatments [10] - The company is expanding the Europat label and working on additional doses and indications, including trials for patients under 18 [9][11] Market Data and Key Metrics Changes - The overall insurance approval rate for Europat in the U.S. is about 70%, with expectations for gradual improvement [8][35] - Europat is commercially available in over 30 countries, with full reimbursement in four European countries and two international markets [9] - The company anticipates full commercial launches in 10 additional countries in 2026 [9] Company Strategy and Development Direction - The company aims to achieve EUR 500 million in operating cash flow by 2026 and at least EUR 5 billion in annual product revenue by 2030 [7][17] - Ascendis Pharma is focused on expanding its pipeline of blockbuster products and enhancing its global commercial infrastructure [7][16] - The company plans to leverage partnerships to create additional value and accelerate product development [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Europat and SKYTROFA, citing strong clinical value propositions [35] - The company is optimistic about the upcoming approval of TransCon CNP and its potential impact on revenue [22][56] - Management highlighted the importance of patient awareness and advocacy in driving product uptake [48] Other Important Information - The company is advancing its clinical trials for TransCon CNP and SKYTROFA, with significant data supporting their efficacy [12][51] - Ascendis Pharma is committed to maintaining independence and profitability as it grows, focusing on long-term value creation [93] Q&A Session Summary Question: Confidence level heading into the TransCon CNP PDUFA - Management expressed high confidence in the approval of TransCon CNP, similar to previous product approvals [28] Question: Insurance approval rate for Europat - Management is satisfied with the current 70% approval rate and noted that reaching 100% is unlikely due to natural filtering in patient eligibility [32][35] Question: Europat pricing and net pricing trends - Management does not discuss net pricing but expects stable revenue growth based on prescription increases [42][43] Question: Usage of Europat among prescribers - There is broad uptake among prescribers, with some treating multiple patients, indicating growing confidence in the product [47] Question: Confidence in Europat growth outside the U.S. - Management noted that uptake varies by country, with different speeds of penetration based on local market conditions [60] Question: TransCon CNP launch expectations - Management anticipates a strong initial uptake for TransCon CNP, leveraging U.S. approval for international markets [56] Question: Strategy for commercializing TransCon CNP globally - The company has established infrastructure through Europat to support rapid global commercialization of TransCon CNP [70] Question: Contribution of products to EUR 5 billion target by 2030 - Management emphasized a diversified product portfolio across multiple indications and regions to achieve sustainable revenue growth [76]